Educational considerations for the clinical introduction and use of remifentanil

Anesthesia and Analgesia

Volumn 89, Issue 4 SUPPL., 1999, Pages

  Reves, J G ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MU OPIATE RECEPTOR AGONIST; REMIFENTANIL;

DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG USE; EDUCATION PROGRAM; HUMAN; MEDICAL EDUCATION; PRIORITY JOURNAL; REVIEW;

EID: 0032834398     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199910001-00002     Document Type: Review

References (6)

1. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics: a preliminary appraisal. Clin Pharmacokinet 1996;29:80-94.
2. Patel SS, Spencer CM. Remifentanil. Drugs 1996;52:417-28.
3. Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (G187084B) in healthy adult male volunteers. Anesthesiology 1993;79:881-92.
4. Hughes MA, Jacobs JR, Glass PSA. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthesia. Anesthesiology 1992;76:334-41.
5. Smith BE, Reves JG, eds. Computer-assisted continuous infusion of intravenous anesthesia drugs. Int Anesthesiol Clin 1995; 33.
6. Albrecht S, Schüttler J, Yarmush J. Postoperative pain management. Anesth Analg 1998;89(Suppl):S40-5.